Meta-Analysis
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 14, 2014; 20(22): 7034-7039
Published online Jun 14, 2014. doi: 10.3748/wjg.v20.i22.7034
Table 2 Baseline characteristics of included trials in the meta-analysis
StudyGroupAgeGenderInterventionTime of interventionBowel preparationColonoscopy staffSedation
(M/F)
Byun et al[20]Hyoscine butylbromideNot mentioned103 (total number)20 mg, ivAt the time of colonoscopic withdrawalNot mentionedNot mentionedNot mentioned
Placebo102 (total number)1 mL NS, iv
Lee et al[21]Hyoscine butylbromide59.4 ± 8.527/3120 mg, ivWhen the scope reached the cecumPolyethylene glycol solutionA single experienced endoscopistMidazolam, 3-5 mg, iv
Placebo58.4 ± 7.923/351 mL NS, iv
Corte et al[10]Hyoscine butylbromide60.6 ± 11.2162/14120 mg, ivAfter the cecum was reachedPrepKit C; picoPrep; moviPrep; glycoPrep8 endoscopists, 14 fellowsMidazolam, fentanyl with or without propofol, iv
Placebo61.4 ± 10.4157/1411 mL NS, iv
de Brouwer et al[15]Hyoscine butylbromide61.5156/18420 mg, ivWhen the cecum was reached and the withdrawal of the colonoscope was startedPolyethylene glycol solution5 gastroenterologists and 3 nurse endoscopistsNot mentioned
Placebo61.4176/1581 mL NS, iv
Rondonotti et al[16]Hyoscine butylbromide57.3 ± 11.590/11220 mg, ivAt cecal intubationSenna-based preparationSix board-certified gastroenterologistsMidazolam and pethidine, iv
Placebo57.3 ± 13.587/1131 mL NS, iv